Differentiation through a broad lineup of research reagents, cell products and contract services
First written in FY2017-Q1. 17 of 30 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-10-09.
3 other companies' latest entry also says "Advanced".
- 2026-10-09AdvancedOther Disclosures
「当社は、このたび、ヒト三次元皮膚モデル「REPROSKIN™」の販売を開始したことをお知らせします。」
ヒト三次元皮膚モデル「REPROSKIN™」の販売開始により、研究試薬・細胞製品の品ぞろえが具体的に拡大した。 - FY2026-H1AdvancedAnnual report
「Leveraging these technological capabilities, in April 2025 we developed and began selling the "StemEdit™ Human iPSC non-HLA" series of HLA-knockout iPSC lines, significantly reducing the risk of immune rejection in regenerative medicine.」
The Company developed and began selling a series of HLA-knockout iPSC lines, expanding its lineup of research reagents and cell products. - FY2025-H1AdvancedAnnual report
「In July 2024, we launched iPS cell-derived exosomes and entered into an agreement appointing JTB Corporation (hereinafter, "JTB") as the exclusive distributor.」
The Company launched iPSC-derived exosomes and began selling them with JTB as the exclusive distributor, expanding its research support and regenerative medicine-related product portfolio. - FY2024AdvancedAnnual report
「In January 2024, we entered into an exclusive distribution agreement in Japan with CellColabs of Sweden and began selling GMP-grade mesenchymal stem cells and exosomes.」
The Company advanced to the stage of adding GMP-grade mesenchymal stem cells and exosomes to its research support and regenerative medicine-related product portfolio and beginning exclusive sales in Japan. - FY2024-Q3AdvancedAnnual report
「In December 2023, we entered into a distributorship agreement with Preci (Ukraine) and began selling primary human hepatocytes in Japan. We also entered into a worldwide distributorship agreement with Nippi and sell MatriMix(511).」
The Company expanded its research support product portfolio by newly launching primary human hepatocytes and MatriMix(511). - FY2024-Q2AdvancedAnnual report
「In September 2023, we began selling in Japan cell measurement instruments made by Nanion Technologies of Germany.」
With respect to its research instrument lineup, the Company began selling cell measurement instruments made by Nanion Technologies of Germany in Japan in September 2023, expanding its product portfolio. - FY2024-Q1RestatedAnnual report
「Specifically, these offerings include research reagent products, disease-model cell production services using iPSCs, human biological sample banking and supply, and pharmacology and efficacy testing services for new drugs using human tissues.」
The Company has reaffirmed its differentiation policy of offering a broad range of products and services, including research reagents, disease-model cells, biological sample banking, and pharmacology and efficacy testing using human tissues. - FY2023-Q3RestatedAnnual report
「In addition to the research products and services described above, we sell research instruments, including cell measurement instruments made by Axion BioSystems of the United States and single-cell analysis instruments made by Blacktrace Holdings of the United Kingdom.」
The Company has reaffirmed its broad lineup combining research reagents, cells, contract services, and research instruments. - FY2023-Q2RestatedAnnual report
「Specifically, these offerings include research reagent products for iPSC research, disease-model cell production services using patient tissue to generate iPSCs, pharmacology and efficacy testing services for new drugs using human tissues, and human biological sample banking.」
The Company has reaffirmed its differentiation policy of providing a broad range of offerings, including research reagents, disease-model cells, evaluations using human tissues, and biological sample banking. - FY2023-Q1RestatedAnnual report
「In addition to the research products and services described above, we sell research equipment, including cell measurement instruments from Axion BioSystems, Inc. (United States) and single-cell analysis instruments from Blacktrace Holdings Ltd. (United Kingdom). These instruments are used to apply our iPS cells and disease model cells to drug discovery screening. By selling cells and instruments through a single channel, we provide customers with comprehensive solutions.」
The Company has reaffirmed a lineup that adds research instruments to research reagents, cells, and contract services to provide comprehensive solutions integrating cells and instruments. - FY2022-Q3RestatedAnnual report
「In addition to the research products and services described above, we sell research equipment, including cell measurement instruments from Axion BioSystems, Inc. (United States) and single-cell analysis instruments from Blacktrace Holdings Ltd. (United Kingdom). These instruments are used to apply our iPS cells and disease model cells to drug discovery screening. By selling cells and instruments through a single channel, we provide customers with comprehensive solutions.」
The Company has reaffirmed its policy of providing comprehensive solutions that integrate cells and instruments by combining research reagents, cells, contract services, and research instruments. - FY2022-Q1AdvancedAnnual report
「In addition to the research products and services described above, we sell research equipment, including cell measurement instruments from Axion BioSystems, Inc. (United States) and single-cell analysis instruments from Blacktrace Holdings Ltd. (United Kingdom). These instruments are used to apply our iPS cells and disease model cells to drug discovery screening. By selling cells and instruments through a single channel, we provide customers with comprehensive solutions.」
In addition to its existing research reagents, cells, and contract services, the Company has stated that it sells research instruments, including single-cell analysis instruments made by Blacktrace Holdings, broadening its product range toward comprehensive solutions that combine cells and instruments. - FY2021AdvancedAnnual report
「We use our network of U.S. medical institutions and expertise in biological sample banking to collect biological samples from patients with COVID-19 and provide them to pharmaceutical companies worldwide.」
The Company expanded its existing human biological sample banking platform to collect samples from COVID-19 patients and provide them to pharmaceutical companies. - FY2021-Q3RestatedAnnual report
「Specifically, these offerings include research reagents for iPSC research, disease-model cell production using patient tissue to generate iPSCs, pharmacology and efficacy evaluation of new drugs using human tissues, and human biological sample banking. The Company's greatest strength is its broad offering of cutting-edge products and services relating to human cells.」
The Company has reaffirmed its differentiation strategy of providing a broad range of human cell-related products and services, including research reagents, disease-model cells, evaluations using human tissues, and biological sample banking. - FY2021-Q2RestatedAnnual report
「Specifically, these offerings include research reagents for iPSC research, disease-model cell production using patient tissue to generate iPSCs, pharmacology and efficacy evaluation of new drugs using human tissues, and human biological sample banking. The Company's greatest strength is its broad offering of cutting-edge products and services relating to human cells.」
The Company has reaffirmed its differentiation strategy of providing a broad range of human cell-related products and services, including research reagents, disease-model cells, evaluations using human tissues, and biological sample banking. - FY2021-Q1RestatedAnnual report
「Specifically, these offerings include research reagents for iPSC research, disease-model cell production using patient tissue to generate iPSCs, pharmacology and efficacy evaluation of new drugs using human tissues, and human biological sample banking. The Company's greatest strength is its broad offering of cutting-edge products and services relating to human cells.」
The Company has reaffirmed its differentiation strategy of providing a broad range of human cell-related products and services, including research reagents, disease-model cells, evaluations using human tissues, and biological sample banking. - FY2020RestatedAnnual report
「In September 2019, we entered into an agreement with Axion BioSystems of the United States to act as its distributor in Japan and began selling its cell-function measurement instruments. The Company had previously focused primarily on selling research products and providing contract services, but by adding instruments to its portfolio, it will provide customers with more comprehensive solutions.」
The Company has reaffirmed its policy of providing comprehensive solutions by adding cell-function measurement instruments to its portfolio alongside research reagents, cells, and contract services. - FY2020-Q3RestatedAnnual report
「Specifically, these offerings include research reagents for iPSC research, disease-model cell production using patient tissue to generate iPSCs, pharmacology and efficacy evaluation of new drugs using human tissues, and human biological sample banking. The Company's greatest strength is its broad offering of cutting-edge products and services relating to human cells.」
The Company has reaffirmed its differentiation strategy of providing a broad range of human cell-related products and services, including research reagents, disease-model cells, evaluations using human tissues, and biological sample banking. - FY2020-Q2AdvancedAnnual report
「The addition of these products further expanded the Company's iPSC product portfolio.」
The Company's iPSC-related product lineup was expanded through sales agency agreements for products made by Axion BioSystems and NeuCyte. - FY2020-Q1AdvancedAnnual report
「Significant progress was made in the biorepository business during the first quarter of the consolidated fiscal year. Specifically, to conduct large-scale collection and banking of biological samples in cooperation with the Kamineni Group, a major hospital group in India, Biorepository LLC, a joint venture between the Company and Fox Chase Cancer Center, established a new joint venture with Kamineni Life Sciences Pvt. Ltd. The Company will significantly expand its biological sample banking business going forward.」
The Company established a new joint venture with India's Kamineni Group concerning its existing procurement platform for human tissues and biological samples, advancing to the stage of expanding large-scale collection and banking. - FY2019-Q3AdvancedAnnual report
「As a new business in research support, we began providing disease-model cell production services using gene-modification technology in collaboration with GenAhead Bio, an investee company of the Company, in October 2018. GenAhead Bio is a team of genome-editing specialists with proprietary "SNIPER" technology enabling highly accurate and efficient genome editing.」
The Company began disease-model cell production services using gene-modification technology in collaboration with GenAhead Bio in October 2018, advancing the research support service line into the operational stage. - FY2019-Q2AdvancedAnnual report
「As a new business in research support, we will advance the development of disease-model cell production services using gene-modification technology in collaboration with GenAhead Bio, an investee company of the Company.」
With respect to its research support offerings, the Company advanced to the stage of developing disease-model cell production services using gene-modification technology as a new business in collaboration with GenAhead Bio. - FY2019-Q1RestatedAnnual report
「We have also assembled a broader lineup of human cells by directly collecting from people cancer cells and human tissues that are difficult to produce from human iPSCs. By offering a broad range of human iPSCs and human tissues in this way, we will further enhance our competitive advantage.」
The Company has reaffirmed its policy of enhancing its competitive advantage through a broad product and service lineup combining human iPSCs with directly collected cancer cells and human tissues. - FY2018AdvancedAnnual report
「We developed the human iPSC culture medium "ReproMed iPSC Medium" as a clinical research reagent for regenerative medicine and began selling it in April 2018. We also developed and launched the human iPSC cryopreservation medium "ReproCryo RM" as a reagent for regenerative medicine products.」
With respect to its research support offerings, the Company developed culture and cryopreservation media for clinical research in regenerative medicine and advanced to the stage of launching and commercializing these products. - FY2018-Q3RestatedAnnual report
「We have also assembled a broader lineup of human cells by directly collecting from people cancer cells and human tissues that are difficult to produce from human iPSCs. By offering a broad range of human iPSCs and human tissues in this way, we will further enhance our competitive advantage.」
The Company has reaffirmed its policy of enhancing its competitive advantage by establishing a broad lineup that includes human iPSCs, directly collected cancer cells, and human tissues. - FY2018-Q1AdvancedAnnual report
「During the first quarter of the consolidated fiscal year, REPROCELL USA entered into a strategic business partnership with Fox Chase Cancer Center (FCCC), a U.S. cancer center, to significantly increase its ability to procure human tissues. This will enable the Company to supply high-quality cancer tissues collected at FCCC, and it will also advance a joint cancer tissue banking project in India.」
Through a strategic business partnership with FCCC, the Company established a supply framework for high-quality cancer tissues and expanded its foundation for research support services involving human tissues by advancing a joint cancer tissue banking project in India. - FY2017AdvancedAnnual report
「In drug discovery support, we are expanding our product lineup by newly adding contract services using human tissues and three-dimensional culture technologies, in addition to human iPSCs.」
The Company expanded its drug discovery support product and service lineup by adding contract services using human tissues and three-dimensional culture technologies. - FY2017-Q3AdvancedAnnual report
「During the first 3 quarters of the consolidated fiscal year, we began selling the new "StemRNA -NM Reprogramming Kit," which commercializes next-generation RNA reprogramming technology for generating iPSCs from cells in urine. The product complies with GMP requirements, and when used in combination with ReproCELL USA's culture medium "NutriStem," it may eventually enable the production of regenerative medicine-grade iPSCs.」
The Company began selling a new product commercializing next-generation RNA reprogramming technology, expanding its lineup of GMP-compliant products. - FY2017-Q2AdvancedAnnual report
「During the first 2 quarters of the consolidated fiscal year, the Group participated in more than 10 overseas and domestic academic conferences and seminars and conducted promotional activities, including corporate exhibitions.」
In addition to participating in more than 10 academic conferences and seminars, the Company began selling 3 new products through sales partnerships for products made by other companies, expanding its product range and promotional activities. - FY2017-Q1First statedAnnual report
「We offer nearly all the reagents required for iPSC research, including reprogramming reagents, culture media, dissociation solutions, cryopreservation media, coating agents, and antibodies.」
The Company provides a broad range of research reagents, human cells and disease-model cells, cell culture and molecular analysis services, and other products and services to meet customer needs and differentiate itself from competitors.